Niacin

Present Knowledge in Nutrition: Tenth Edition

Volumn , Issue , 2012, Pages 293-306

  Penberthy, Todd W ^a   Kirkland, James B ^b  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF GUELPH   (Canada)

Author keywords

NAD metabolism, niacin to NAD by metabolic pathways; NAD, sirtuin HDAC, altering NAD and ultimately chromatin structure; Niacin biochemical assessment, measuring tissue NAD levels; Niacin deficiency disease pellagra, devastating nutritional disease; Niacin into essential pyridine nucleotides NAD P ; Niacin structure and nomenclature; Niacin, as nicotinic acid or nicotinamide, vitamin B3; Niacin, finding the pharmacology NAD precursor in disease response; Niacin responsive genetic disorders, mutations in neutral amino acid transporter; Pathway forming, utilizing NAD, de novo, Preiss Handler, salvage pathways

Indexed keywords

EID: 84886969010     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119946045.ch19     Document Type: Chapter

References (75)

1. Adalbert, R., Gillingwater, T.H., Haley, J.E., et al. (2005) A rat model of slow Wallerian degeneration (WldS) with improved preservation of neuromuscular synapses. Eur J Neurosci 21, 271-277.
2. Altschul, R., Hoffer, A., and Stephen, J.D. (1955) Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 54, 558-559.
3. Ames, B.N., Elson-Schwab, I., and Silver, E.A. (2002) High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. Am J Clin Nutr 75, 616-658.
4. Araki, T., Sasaki, Y., and Milbrandt, J. (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305, 1010-1013.
5. Barbosa, M.T., Soares, S.M., Novak, C.M., et al. (2007) The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J 21, 3629-3639.
6. Belenky, P., Racette, F.G., Bogan, K.L., et al. (2007) Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD +. Cell 129, 473-484.
7. Benavente, C.A., Jacobson, M.K., and Jacobson, E.L. (2009) NAD in skin: therapeutic approaches for niacin. Curr Pharm Des 15, 29-38.
8. Bieganowski, P. and Brenner, C. (2004) Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD + in fungi and humans. Cell 117, 495-502.
9. Canner, P.L., Berge, K.G., Wenger, N.K., et al. (1986) Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8, 1245-1255.
10. Carlson, L.A. (2005) Nicotinic acid: the broad-spectrum lipid dru. A 50th anniversary review. J Intern Med 258, 94-114.
11. Carlson, L.A. and Rosenhamer, G. (1988) Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223, 405-418.
12. Carpenter, K.J. (1981) Effects of different methods of processing maize on its pellagragenic activity. Fed Proc 40, 1531-1535.
13. Corder, E.H., Saunders, A.M., Risch, N.J., et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7, 180-184.
14. Corder, E.H., Saunders, A.M., Strittmatter, W.J., et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
15. De Flora, A., Zocchi, E., Guida, L., et al. (2004) Autocrine and paracrine calcium signaling by the CD38/NAD + /cyclic ADP-ribose system. Ann N Y Acad Sci 1028, 176-191.
16. Dreizen, S., McCredie, K.B., Keating, M.J., et al. (1990c) Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad Med 87, 163-167, 170.
17. Etheridge, E.W. (1972) The Butterfly Caste: A Social History of Pellagra in the South. Greenwood Publishing, Westport, Conn.
18. Feng, Y., Yan, T., Zheng, J., et al. (2010) Overexpression of Wld(S) or Nmnat2 in mauthner cells by single-cell electroporation delays axon degeneration in live zebrafish. J Neurosci Res 88, 3319-3327.
19. Fu, C.S., Swendseid, M.E., Jacob, R.A., et al. (1989) Biochemical markers for assessment of niacin status in young men: levels of erythrocyte niacin coenzymes and plasma tryptophan. J Nutr 119, 1949-1955.
20. Fukuwatari, T., Sugimoto, E., and Shibata, K. (2002) Growth-promoting activity of pyrazinoic acid, a putative active compound of antituberculosis drug pyrazinamide, in niacin-deficient rats through the inhibition of ACMSD activity. Biosci Biotechnol Biochem 66, 1435-1441.
21. Ganapathy, V., Thangaraju, M., and Prasad, P.D. (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121, 29-40.
22. Gensler, H.L., Williams, T., Huang, A.C., et al. (1999) Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer 34, 36-41.
23. Gille, A., Bodor, E.T., Ahmed, K., et al. (2008) Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 48, 79-106.
24. Gilley, J. and Coleman, M.P. (2010) Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol 8, e1000300.
25. Goody, M.F., Kelly, M.W., Lessard, K.N., et al. (2010) Nrk2b-mediated NAD + production regulates cell adhesion and is required for muscle morphogenesis in vivo: Nrk2b and NAD + in muscle morphogenesis. Dev Biol 344, 809-826.
26. Gupta, M.P., Rajamohan, S.B., Sundarasean, N.R., et al. (2008c) SIRT1 prevents cell death by deacetylating PARP1 and suppressing its enzymatic activity. Paper presented at: PARP 2008 (Tucson, Arizona).
27. Guyton, J.R. and Bays, H.E. (2007) Safety considerations with niacin therapy. Am J Cardiol 99, 22C-31C.
28. Hoffer, A., Osmond, H., Callbeck, M.J., et al. (1957) Treatment of schizophrenia with nicotinic acid and nicotinamide. J Clin Exp Psychopathol 18, 131-158.
29. Howitz, K.T., Bitterman, K.J., Cohen, H.Y., et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196.
30. Jacobson, E.L. (1993) Niacin deficiency and cancer in women. J Am Coll Nutr 12, 412-416.
31. Jacobson, E.L. and Jacobson, M.K. (1997) Tissue NAD as a biochemical measure of niacin status in humans. Methods Enzymol 280, 221-230.
32. Jacobson, E.L., Shieh, W.M., and Huang, A.C. (1999) Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis. Mol Cell Biochem 193, 69-74.
33. Kamanna, V.S. and Kashyap, M.L. (2008c) Mechanism of action of niacin. Am J Cardiol 101, 20B-26B.
34. Karpe, F. and Frayn, K.N. (2004) The nicotinic acid receptor-a new mechanism for an old drug. Lancet 363, 1892-1894.
35. Kirkland, J.B. (2009a) Niacin status impacts chromatin structure. J Nutr 139, 2397-2401.
36. Kirkland, J.B. (2009b) Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharm Des 15, 3-11.
37. Klein, C., Grahnert, A., Abdelrahman, A., et al. (2009) Extracellular NAD(+) induces a rise in [Ca(2 +)](i) in activated human monocytes via engagement of P2Y(1) and P2Y(11) receptors. Cell Calcium 46, 263-272.
38. Kolata, G. (2009) Advances elusive in the drive to cure cance. New York Times. http://www.nytimes.com/2009/04/24health/policy/24cancer.html?pagewanted=all.
39. Kowalski, R.E. (2001) The New 8-Week Cholesterol Cure: The Ultimate Program for Preventing Heart Disease. Harper Collins, New York.
40. Mack, T.G., Reiner, M., Beirowski, B., et al. (2001) Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 4, 1199-1206.
41. Mayer, P.R., Huang, N., Dewey, C.M., et al. (2010) Expression, localization and biochemical characterization of NMN adenylyltransferase 2. J Biol Chem 285, 40387-40396.
42. McCormick, D.B. and Greene, H.L. (1999) Vitamins. In C.A. Burtis and E.R. Ashwood (eds), Textbook of Clinical Chemistry. WH Saunders, Philadelphia, pp. 999-1029.
43. Mellor, A.L. and Munn, D.H. (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4, 762-774.
44. Morris, M.C., Evans, D.A., Bienias, J.L., et al. (2004) Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatr 75, 1093-1099.
45. Mutafova-Yambolieva, V.N., Hwang, S.J., Hao, X., et al. (2007) Beta-nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle. Proc Natl Acad Sci USA 104, 16359-16364.
46. Nebert, D.W. and Russell, D.W. (2002) Clinical importance of the cytochromes P450. Lancet 360, 1155-1162.
47. Niinisalo, P., Oksala, N., Levula, M., et al. (2010). Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study. Ann Med 42, 55-63.
48. Nozaki, J., Dakeishi, M., Ohura, T., et al. (2001) Homozygosity mapping to chromosome 5p15 of a gene responsible for Hartnup disorder. Biochem Biophys Res Commun 284, 255-260.
49. Oakley, A. and Wallace, J. (1994) Hartnup disease presenting in an adult. Clin Exp Dermatol 19, 407-408.
50. Otten, J.J., Hellwig, J. P., and Meyers, L.D. (eds) (2006) Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. National Academies Press, Washington, DC.
51. Partida-Sanchez, S., Rivero-Nava, L., Shihi, G., et al. (2007) CD38: an ecto-enzyme at the crossroads of innate and adaptive immune responses. Adv Exp Med Biol 590, 171-183.
52. Patel, A.B. and Prabhu, A.S. (2008) Hartnup disease. Indian J Dermatol 53, 31-32.
53. Penberthy, W.T. (2007) Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease. Curr Drug Metab 8, 245-266.
54. Penberthy, W.T. and Tsunoda, I. (2009) The importance of NAD in multiple sclerosis. Curr Pharm Des 15, 64-99.
55. Qin, W., Yang, T., Ho, L., et al. (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281, 21745-21754.
56. Ramsey, K.M., Mills, K.F., Satoh, A., et al. (2008) Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7, 78-88.
57. Revollo, J.R., Grimm, A.A., and Imai, S. (2004). The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279, 50754-50763.
58. Sasaki, Y., Araki, T., and Milbrandt, J. (2006) Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci 26, 8484-8491.
59. Sasaki, Y., Vohra, B.P., Baloh, R.H., et al. (2009) Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. J Neurosci 29, 6526-6534.
60. Scarmeas, N. (2007) Invited commentary: lipoproteins and dementia-is it the apolipoprotein A-I? Am J Epidemiol 165, 993-997.
61. Schraufstatter, I.U., Hinshaw, D.B., Hyslop, P.A., et al. (1986) Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest 77, 1312-1320.
62. Schrocksnadel, K., Wirleitner, B., Winkler, C., et al. (2006) Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 364, 82-90.
63. Shah, G.M., Shah, R.G., Veillette, H., et al. (2005) Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol 100, 2307-2314.
64. Shall, S. and de Murcia, G. (2000) Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 460, 1-15.
65. Symula, D.J., Shedlovsky, A., Guillery, E.N., et al. (1997) A candidate mouse model for Hartnup disorder deficient in neutral amino acid transport. Mamm Genome 8, 102-107.
66. Tang, K., Sham, H., Hui, E., et al. (2008) Niacin deficiency causes oxidative stress in rat bone marrow cells but not through decreased NADPH or glutathione status. J Nutr Biochem 19, 746-753.
67. Thangaraju, M., Cresci, G.A., Liu, K., et al. (2009) GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res 69, 2826-2832.
68. USDA/ARS (2005) USDA National Nutrient Standard Database, Release 18. US Department of Agriculture/Agricultural Research Service, Washington, DC. Retrieved December 23, 2005, from www.ars.usda.gov/ba/bhnrc/ndl.
69. Uyttenhove, C., Pilotte, L., Theate, I., et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9, 1269-1274.
70. van der Hoorn, J.W., de Haan, W., Berbee, J.F., et al. (2008) Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE * 3Leiden. CETP mice. Arterioscler Thromb Vasc Biol 28, 2016-2022.
71. Yan, T., Feng, Y., Zheng, J., et al. (2010) Nmnat2 delays axon degeneration in superior cervical ganglia dependent on its NAD synthesis activity. Neurochem Int 56, 101-106.
72. Yang, H.J., Yen, M.C., Lin, C.C., et al. (2010) A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity. Exp Biol Med (Maywood) 235, 869-876.
73. Ying, W. (2007) NAD + and NADH in brain functions, brain diseases and brain aging. Front Biosci 12, 1863-1888.
74. Young, G.S. and Kirkland, J.B. (2008) The role of dietary niacin intake and the adenosine-5 ′-diphosphate-ribosyl cyclase enzyme CD38 in spatial learning ability: is cyclic adenosine diphosphate ribose the link between diet and behaviour? Nutr Res Rev 21, 42-55.
75. Zhai, R.G., Zhang, F., Hiesinger, P.R., et al. (2008) NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature 452, 887-891.